Debiopharm

Marc Cikes from our Innovation Fund will be attending at the upcoming Swiss-Korean Life Science Symposium. Marc will be presenting in the session on AI in Healthcare, sharing insights on “Driving the transformation of healthcare, a pharma perspective”. This annual event organized by the Swiss-Korean Life Science Initiative brings together pioneering minds from Switzerland and Korea—including public research institutions, leading hospitals, industry, startups and thought leaders in healthcare and digital technologies—to foster international collaboration and innovation in healthcare. Looking forward to the ideas and connections that will come out of this remarkable gathering! More info 👉 https://www.skls.or.kr/ #HealthcareInnovation #AI #Pharma #LifeSciences

Navigating life with breast cancer is often compared to enduring a period of crisis - a crisis of the body, but also a shift in how others perceive you. In this interview, Lina Prosa and her fellow colleagues from the Centro Amazzone, a renowned Italian patient support group, discuss how theater and Greek mythology serve as cathartic metaphors for the battle against cancer.  If you enjoyed this interview, consider following Debiopharm and stay tuned for the next one! We believe that creative solutions like Centro Amazzone are offering women with breast cancer a better quality of life. Learn more about how we seek to ease patient disease burden here: https://lnkd.in/eZAttCq8

Artificial Intelligence (AI) is rapidly transforming the drug discovery process, turning hype into tangible real-world results. Companies like Iktos and VeriSIM Life, both part of our Innovation Fund's portfolio, are leading the charge in revolutionizing drug design through cutting-edge AI platforms. iktos uses AI to optimize drug discovery by integrating generative molecule design, synthesis and testing, while VeriSIM Life uses hybrid models to reduce animal testing and improve clinical success prediction. As highlighted in a recent report, these innovative approaches are driving real progress in healthcare! Discover more on our website! 👇 #AI #DrugDiscovery #Innovation #HealthTech

Breast cancer is the most common cancer diagnosed in women and the second most common cause of death from cancer among women worldwide. From a subtle pink ribbon to a bold pink suit, this month, our employees showed up in all shades of pink to show solidarity with all individuals affected by breast cancer. At Debiopharm, patient centricity is at the heart of our drug development. Learn more about how we seek to ease patient disease burden here: https://lnkd.in/eZAttCq8 #BreastCancerAwareness #Cancer #Solidarity #PinkOctober #lifeatdebio

We were invited to the Swiss Embassy in Paris to participate in a two-day event on October 14th and 15th, featuring partnering meetings and concluding with a networking cocktail. This opportunity allowed us to connect with innovative biotech companies and explore cutting-edge science within the French ecosystem.   🗣️ During the evening of the 15th, we had the honor of attending speeches by Yachar Nafissi-Azar, Minister-Counsellor and Deputy Head of Mission at the French Embassy, and our CEO, Bertrand Ducrey, underlined the importance of fostering fruitful collaborations, development opportunities and strengthen contacts between the Swiss and French ecosystems.   We sincerely express our gratitude towards, Elena Voicu, Michaël Ehrlich, Maya Rolewicz, Yachar Nafissi-Azar and the whole Swiss Business Hub France team for their warm welcome and their support.   At Debiopharm, we are constantly looking for new early-stage medicines and innovative treatment approaches, therefore, we renew our invite to biotech and pharmaceutical companies to submit your projects here to start a collaboration today!: https://lnkd.in/ebrEyree #innovation #biotech #pharma #digitalhealth

At the beginning of October, we announced receiving a visit from the famous Italian breast cancer support group, the Centro Amazzone. Today, we share the first of three interviews, in which Anna Barbera, one of the two founders, narrates how, from a dramatic event like breast cancer, an earth-shattering initiative can be born. If you liked this interview, consider following Debiopharm and stay tuned for the next two interviews! We believe that creative solutions like Centro Amazzone are offering women with breast cancer a better quality of life. Learn more about how we seek to ease patient disease burden here: https://lnkd.in/eZAttCq8 #breastcancer #patientsupport #prevention #oncology

☀ HLTH USA 2024 in Las Vegas is around the corner and Marc Cikes and Tom Gibbs from our Innovation Fund team will be there! HLTH USA is one of the most groundbreaking events in healthcare innovation, bringing together industry leaders, startups, and visionaries to reshape the future of #AI, #HealthTech, and #DigitalHealth. We’re looking forward to learning, networking, and getting inspired by the pioneers driving transformation. 💡 If you’re attending as well, let’s connect! We're always on the lookout for new investment opportunities so if you have a innovative project that could benefit from investment support, don't miss this chance to catch up with us! #HLTHUSA #DigitalHealth #HealthcareInnovation #Startups

Did you know that most bone & joint infections are caused by staphylococci bacteria which are known to easily become drug-resistant? What if we could have an ultra-narrow approach to treat such infections while minimizing the rise of antibiotic resistance? That's where our development is focused! In this interview, our Principal Clinical Scientist, Alireza Shamaei-Tousi, quickly summarizes the most important information you need to know about our ongoing phase 2 clinical trial. Click below to know more 👇 : About Afabicin: https://lnkd.in/dFkj_j-P About Debiopharm's expertise in antibiotic development: https://lnkd.in/emFuSTqy

Is treatment with an ultra narrow-spectrum antibiotic comparable to the standard of care in patients with Bone & Joint infections? Is there potential for sharper pathogen-specificity and microbiome-sparing activity? These and many other questions will be answered by our Principal Clinical Scientist, Alireza Shamaei-Tousi, and our Senior Scientist, David Cameron, this week at IDWeek 2024 in Los Angeles. Find more information in the press release below 👇 and, if you're interested to know more about Debiopharm's expertise in antibiotic development, click on the following link: https://lnkd.in/eayVHfPn #antibiotics #drugdevelopment #antibioticresistance #publichealth

Our Innovation Fund is excited to attend Frontiers Health 2024 in Berlin! 🚀 Come and meet Vincent Lepreux and Nicolas Stalder from our Innovation Fund team at the event. Frontiers Health has emerged as one of the premier global health innovation events, with a strong focus on digital therapies, breakthrough technologies, healthcare transformation, investments, and ecosystem development. 💡 If you have a groundbreaking project that could benefit from investment support, don't miss this chance to catch up with us! We're always on the lookout for new investment opportunities. #DigitalHealth #Innovation #FH24 #Investment